Skip to main content

Day: March 17, 2023

Reporting of transactions in Agillic A/S shares by four persons with managerial responsibilities

Announcement no. 4 2023 Copenhagen – 17 March 2023 – Agillic A/S (Nasdaq First North Growth Market Denmark: AGILC) – Reporting of transactions in Agillic A/S shares by four persons with managerial responsibilities Agillic A/S has received notification pursuant to Article 19 of the Market Abuse Regulation of transactions related to shares in Agillic A/S made by four persons with managerial responsibilities in Agillic and/or persons closely associated with them. The notification is related to the transaction announced on 14 March 2023 in Company Announcement 02-2023. For further information, please contact:Emre Gürsoy, CEO, Agillic A/S+45 30 78 42 00emre.gursoy@agillic.com Claus Boysen, CFO, Agillic A/S+45 28 49 18 46claus.boysen@agillic.com Certified AdviserJohn Norden, Norden CEF A/S About Agillic A/SAgillic is a Danish software company...

Continue reading

Chart Industries Completes the Acquisition of Howden

2023 Calendar Guidance Chart IndustriesCreates a differentiated leading offering across stationary and rotating equipment for multiple applications and end markets, including industrial gas, hydrogen, LNG, water treatment, carbon capture, and energy transition On track to meet or exceed its previously announced targets for $175 million of annualized cost synergies and $150 million of commercial synergies in the first 12 months of ownership Provides calendar year 2023 guidance for the addition of Howden in line with previously communicated rangesATLANTA, March 17, 2023 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS) (“Chart”), a global leader in engineering and manufacturing of process technology and equipment for industrial gas, specialty and energy transition markets, has completed its acquisition of Howden, a leading...

Continue reading

American Shared Hospital Services Announces Fourth Quarter and Year End 2022 Earnings Conference Call

Conference Call on Friday March 24th, 2023 at 1:00 pm ET / 10:00 am PT SAN FRANCISCO, CA, March 17, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its fourth quarter and year end 2022 financial results on Friday March 24th, 2023 at 1:00 pm ET / 10:00 am PT. The fourth quarter and year end 2022 financial results press release will be issued before the market open on Friday March 24th, 2023. Teleconference Date/Time Friday March 24th, 2023 at 1:00 pm ET / 10:00 am PT Teleconference and Webcast Information To participate, please call 1 (844)...

Continue reading

Kaival Brands Reports Fiscal 2023 First Quarter Financial Results

Company significantly bolsters distribution following agreements with national brokers GRANT-VALKARIA, Fla., March 17, 2023 (GLOBE NEWSWIRE) — Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) (“Kaival Brands,” the “Company” or “we,” “our” or similar terms), the exclusive distributor of all products manufactured by Bidi Vapor, LLC (“Bidi Vapor”), including the BIDI® Stick electronic nicotine delivery system (ENDS), which are intended for adults 21 and over, today announced its financial results for the fiscal 2023 first quarter ended January 31, 2023. Recent Business During and Subsequent to the Fiscal First Quarter 2023On March 9, 2023, the Company announced it had signed an agreement with a prominent national broker, increasing distribution by upwards of 40,000 retail stores. On March 7, 2023, the Company announced...

Continue reading

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Enrollment Underway in Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a corporate update. “With the initiation of our INDP-D101 trial at the end of December 2022 and the subsequent dosing of our first patient in the first cohort, we are well underway in our Phase 1 trial of Decoy20 for the treatment of solid tumors,” said Jeffrey Meckler, chief executive officer of Indaptus. “Following the initial dosing we were encouraged to learn that the subject experienced manageable and expected adverse events related to the immune response we anticipated. We are...

Continue reading

AGF Announces March 2023 Cash Distributions for Certain AGF ETFs

TORONTO, March 17, 2023 (GLOBE NEWSWIRE) — AGF Investments Inc. (TSX:AGF.B) (AGF) today announced the March 2023 cash distributions for AGF Systematic Global Multi-Sector Bond ETF, AGF Systematic Global Infrastructure ETF, AGF Global Sustainable Growth Equity ETF and AGF Global Opportunities Bond ETF, which pay quarterly distributions. Unitholders of record on March 27, 2023 will receive cash distributions payable on March 31, 2023. Details regarding the final “per unit” distribution amounts are as follows:ETF Ticker Exchange Cash Distribution Per Unit ($)AGF Systematic Global Multi-Sector Bond ETF QGB NEO Exchange $0.17AGF Systematic Global Infrastructure ETF QIF NEO Exchange $0.21AGF Global Sustainable Growth Equity ETF AGSG NEO Exchange $0.01AGF Global Opportunities Bond ETF AGLB NEO Exchange $0.17Further...

Continue reading

Form 8.3 – [EMIS GROUP PLC 16 03 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree EMIS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Form 8.3 – [DEVRO PLC 16 03 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree DEVRO PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Wrap® to Host Investor Insights Webcast on March 23, 2023

TEMPE, Ariz., March 17, 2023 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (Nasdaq: WRAP) (“Wrap” or the “Company”), a global leader in innovative public safety technologies and services, will host a third edition of its Investor Insights webcast on March 23, 2023. During the webcast, Wrap executives will recap the Company’s attendance at the World Police Summit and take related questions from investors. Interested parties may submit questions to the Company prior to the webcast at WRAP@gatewayir.com by 8:00 p.m. Eastern time on Wednesday, March 22, 2023. Questions will be addressed based on the relevance to the topics of this webinar and public disclosure rules. Date: Thursday, March 23, 2023Time: 10:00 AM Eastern time (7:00 AM Mountain time)Webcast Link: Click here to register Please join the webcast 5-10 minutes prior to the start...

Continue reading

Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman and Acting Chief Executive Officer, purchased 25,000 common shares at $0.58 per share, bringing his total holding to 38,640,737 common shares. About ForalumabActivated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor, dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets, an effect demonstrated in patients with COVID and with multiple sclerosis, as well as...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.